Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945458 | 1.00 | NR1H2 (0.41) | NR1H2ALDH1A1SMN1; SMN2TP53PTPN2 | |
| SCHEMBL5619854 | 0.90 | CHRM2 (0.46) | NR1H2ALDH1A1SMN1; SMN2TP53DDB1 | |
| SCHEMBL2949898 | 0.88 | HSD17B10 (0.46) | NR1H2ALDH1A1SMN1; SMN2TP53PTPN2 | |
| SCHEMBL2949901 | 0.88 | HSD17B10 (0.46) | NR1H2ALDH1A1SMN1; SMN2TP53PTPN2 | |
| SCHEMBL1583351 | 0.85 | CHRM2 (0.49) | NR1H2ALDH1A1SMN1; SMN2TP53DDB1 | |
| SCHEMBL1583349 | 0.85 | CHRM2 (0.49) | NR1H2ALDH1A1SMN1; SMN2TP53DDB1 | |
| SCHEMBL1663196 | 0.85 | CHRM2 (0.49) | NR1H2ALDH1A1SMN1; SMN2TP53DDB1 | |
| SCHEMBL1583858 | 0.84 | TP53 (0.44) | NR1H2ALDH1A1SMN1; SMN2TP53DDB1 | |
| SCHEMBL3069589 | 0.83 | EPHX1 (0.47) | NR1H2ALDH1A1TP53DDB1CRBN | |
| SCHEMBL17894031 | 0.83 | BRD4 (0.40) | ALDH1A1PTPN2PTPN1PTPN6DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737161-B2 | Condensed furan compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20090156803-A1 | Condensed furan compounds | KAWAGUCHI TAKAYUKI | 2009-06-18 | — | — | US | disclosed |
| US-7514449-B2 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| CN-100344632-C | Fused furan compound | TANABE SEIYAKU CO (JP) | 2007-10-24 | — | — | CN | disclosed |
| US-20060094724-A1 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1723210-A | Fused furan compound | TANABE SEIYAKU CO (JP) | 2006-01-18 | — | — | CN | disclosed |
| EP-1582521-A1 | FUSED FURAN COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156803-A1 | Condensed furan compounds | F2, F12, F11 | NR1H2 627/4885ALDH1A1 1627/4885SMN1; SMN2 4447/4885 |
| US-20060094724-A1 | Fused furan compound | F2, F12, F11 | NR1H2 464/4885ALDH1A1 1674/4885SMN1; SMN2 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.